The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Imbruvica faces challenges on multiple fronts.
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.
As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.